Trial Profile
Peptide Receptor Radionuclide Therapy (PRRT) With Radiolabelled Somatostatin Analogue 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors, 18F-2-fluoro-2-deoxy-D-glucose (FDG)-PET Negative Patients: a Prospective Phase II Randomized Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Gastric cancer; Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LUNET
- 13 Sep 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 13 Sep 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.
- 25 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.